情色五月天情色五月天,五月丁香网在线,99香蕉国产精品偷在线观看

您好，歡迎來到拜力生物網(wǎng)站！請登錄注冊

我的訂單 | 聯(lián)系我們 | 在線客服QQ：3012681483 | 客服電話：400-968-7988 | 工作時間：08:30-17:30

主營產(chǎn)品： ELISA試劑盒、抗體、補體血清、兔補體、干擾素、小鼠測溫儀、進口試劑、Quidel代理、Swant代理、PBL Assay Science代理

網(wǎng)站首頁產(chǎn)品中心代理品牌新聞資訊資源中心關(guān)于我們

所在位置：首頁 > 產(chǎn)品中心 > Antibodies > Antibodies產(chǎn)品

訂購信息

上海拜力生物科技公司

Tel:400-968-7988 021-33779008

Anti-PIM1 Antibody

品牌：Antibodies

貨號：

規(guī)格：50μl

貨期：

應(yīng)用：

咨詢客服

立即購買加入購物車

Anti-PIM1 Antibody

商品詳情參考文獻相關(guān)資料

Overview

Name:	Anti-PIM1 Antibody See all PIM1 primary antibodies
Description:	Rabbit monoclonal antibody to PIM1
Specificity:	This antibody detects endogenous levels of PIM1 and does not cross-react with related proteins.
Applications:	WB, ICC/IF, IHC
Reactivity:	Human, Mouse
Immunogen:	Recombinant antibody.
Host:	Rabbit
Clonality:	Monoclonal
Conjugate:	Unconjugated
Molecular Weight:	~ 45 kDa
Purity:	Protein A affinity purified
Product Form:	Recombinant Rabbit Monoclonal Antibody. 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.

Target

Function:	Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.
Tissue Specificity:	Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2 are both expressed in prostate cancer cell lines.
Sequence Similarities:	Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. PIM subfamily.
Post-Translational Modification:	Autophosphorylated on both serine/threonine and tyrosine residues. Phosphorylated. Interaction with PPP2CA promotes dephosphorylation.
Cellular Location:	Cytoplasm. Nucleus.
Database Links:	Entrez Gene: 5292?Human Entrez Gene: 18712?Mouse Omim: 164960?Human SwissProt: P11309?Human SwissProt: P06803?Mouse Unigene: 81170?Human Unigene: 405293?Mouse Unigene: 485038?Mouse
Synonyms:	Oncogene PIM 1 Antibody Oncogene PIM1 Antibody PIM Antibody PIM 1 Antibody Pim 1 kinase Antibody pim 1 kinase 44 kDa isoform Antibody Pim 1 oncogene Antibody pim 1 oncogene (proviral integration site 1) Antibody PIM1 Antibody pim1 kinase 44 kDa isoform Antibody PIM1_HUMAN Antibody Pim2 Antibody PIM3 Antibody Proto oncogene serine/threonine protein kinase Pim 1 Antibody Proto-oncogene serine/threonine-protein kinase Pim-1 Antibody Proviral integration site 1 Antibody Proviral integration site 2 Antibody
Information:	Target information shown above is from the UniProt Consortium.